Anionic Long-Chain Lipid Skin Barrier Attenuation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The skin barrier function, particularly the penetration of hydrophilic molecules larger than 800 Da, is challenging due to the barrier function of the horny layer, limiting the development of effective transdermal administration formulations.
Innovation Solution
A composition containing solid complexes made of a cationic lipid, an anionic lipid, and a nucleic acid or pharmaceutical agent, dispersed in an oil phase, which attenuates the skin barrier function and enhances drug penetration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If the skin barrier function is maintained, then skin protection is improved, but drug penetration is worsened
Solution Approach 1:
The patent uses anionic long-chain lipids to change the physical-chemical parameters of the skin barrier, specifically altering the lipid organization and increasing fluidity in the stratum corneum. This parameter change allows the skin barrier to temporarily become more permeable to drugs while maintaining its protective function, resolving the contradiction between skin protection and drug penetration.
Solution Approach 2:
The anionic long-chain lipid acts as an intermediary substance that mediates between the skin barrier and the drug. It interacts with the skin barrier lipids to modify barrier properties and simultaneously interacts with the drug to facilitate its penetration, thus resolving the contradiction without compromising skin protection.
2Reliability
If hydrophilic molecules larger than 800 Da are administered transdermally, then therapeutic efficacy is improved, but formulation development difficulty is worsened
Solution Approach 1:
The patent employs a composite formulation system consisting of cationic lipids, anionic long-chain lipids, and hydrophilic drugs. The cationic and anionic lipids form complexes that can encapsulate large hydrophilic molecules, creating a composite material that enables transdermal delivery of molecules >800 Da while simplifying the formulation development process.
Solution Approach 2:
The formulation uses anionic long-chain lipids to change the microenvironmental parameters at the skin interface, creating favorable conditions for the penetration of large hydrophilic molecules. This parameter change approach simplifies formulation development by providing a universal mechanism that works for various large hydrophilic drugs.
3Productivity
If anionic long-chain lipid is added to enhance drug penetration, then penetration enhancement is improved, but skin barrier attenuation is worsened
Solution Approach 1:
The patent applies partial action by using sub-saturating amounts of anionic long-chain lipids that are sufficient to enhance drug penetration but insufficient to cause excessive skin barrier damage. This controlled partial action achieves penetration enhancement while maintaining skin barrier integrity and avoiding over-attenuation.
Solution Approach 2:
The anionic long-chain lipid induces controlled parameter changes in the skin barrier, specifically modifying lipid organization and fluidity to enhance penetration. The effect is transient and reversible, allowing the barrier to return to its normal state after drug delivery, thus avoiding permanent damage while achieving penetration enhancement.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition achieves significant enhancement of drug penetration into the skin, allowing for transdermal administration of hydrophilic molecules, including nucleic acids, with increased efficacy compared to traditional formulations.
Implementation Method 1
anionic long-chain lipids attenuate skin barrier function; and that because of this, anionic long-chain lipids are applicable to enhancement of the penetration of drugs into skin
Implementation Method 2
solid complexes each containing a cationic long-chain lipid, an anionic long-chain lipid, and a drug are dispersed in the oil phase
Data Source
Figure 1
Figure 2~3B
Figure 3C
AI summary
The present invention provides a composition for use in attenuating skin barrier, the composition containing an anionic long-chain lipid (in particular, a long-chain fatty acid). The present invention provides a dispersion in which complexes (e.g., solid complexes) each containing a cationic long-chain lipid, an anionic long-chain lipid, and a drug are dispersed.